Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX340 in Participants with Uncontrolled Hypertension
NCT07758634Phase 2Recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 2
01
Overview
A Phase 2 trial of CTX340 in hypertension (HTN), sponsored by CRISPR Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
CTX340
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07758634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758634.